Exelixis, Inc. (NASDAQ:EXEL) – Research analysts at Leerink Swann upped their FY2017 earnings estimates for Exelixis in a report issued on Friday, according to Zacks Investment Research. Leerink Swann analyst M. Schmidt now expects that the biotechnology company will post earnings of $0.45 per share for the year, up from their previous forecast of $0.44. Leerink Swann also issued estimates for Exelixis’ Q1 2018 earnings at $0.11 EPS, Q2 2018 earnings at $0.15 EPS, Q3 2018 earnings at $0.16 EPS, Q4 2018 earnings at $0.21 EPS and FY2020 earnings at $1.77 EPS.
Other research analysts also recently issued reports about the company. Cann reissued a “hold” rating on shares of Exelixis in a report on Monday, October 16th. Oppenheimer reissued a “hold” rating on shares of Exelixis in a report on Monday, October 16th. SunTrust Banks boosted their target price on Exelixis from $32.00 to $35.00 and gave the stock a “buy” rating in a report on Monday, October 16th. Zacks Investment Research raised Exelixis from a “hold” rating to a “buy” rating and set a $32.00 target price on the stock in a report on Wednesday, October 18th. Finally, Stifel Nicolaus reissued a “hold” rating and issued a $26.00 target price on shares of Exelixis in a report on Tuesday, October 17th. Six analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $32.13.
Shares of Exelixis (NASDAQ:EXEL) traded up $0.35 on Monday, hitting $30.66. The stock had a trading volume of 1,811,876 shares, compared to its average volume of 2,940,000. The firm has a market cap of $9,070.00, a P/E ratio of 62.57, a P/E/G ratio of 0.86 and a beta of 1.88. Exelixis has a fifty-two week low of $18.03 and a fifty-two week high of $32.50.
Exelixis (NASDAQ:EXEL) last released its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.18. The company had revenue of $152.50 million for the quarter, compared to the consensus estimate of $104.91 million. Exelixis had a return on equity of 105.47% and a net margin of 36.80%. The company’s quarterly revenue was up 145.2% on a year-over-year basis. During the same period in the previous year, the business earned ($0.04) earnings per share.
In related news, Director Alan M. Garber sold 15,000 shares of the business’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $30.30, for a total value of $454,500.00. Following the completion of the transaction, the director now owns 64,829 shares in the company, valued at approximately $1,964,318.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 5.10% of the company’s stock.
Hedge funds have recently bought and sold shares of the stock. First Quadrant L P CA raised its position in Exelixis by 6,771.4% in the 3rd quarter. First Quadrant L P CA now owns 402,528 shares of the biotechnology company’s stock worth $9,753,000 after purchasing an additional 396,670 shares during the last quarter. Macquarie Group Ltd. bought a new stake in shares of Exelixis during the 2nd quarter valued at $3,449,000. Stevens Capital Management LP raised its position in shares of Exelixis by 55.5% during the 3rd quarter. Stevens Capital Management LP now owns 127,049 shares of the biotechnology company’s stock valued at $3,078,000 after acquiring an additional 45,336 shares during the last quarter. Vident Investment Advisory LLC bought a new stake in shares of Exelixis during the 3rd quarter valued at $783,000. Finally, Schroder Investment Management Group bought a new stake in shares of Exelixis during the 3rd quarter valued at $334,000. Hedge funds and other institutional investors own 80.60% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: “Brokers Offer Predictions for Exelixis, Inc.’s FY2017 Earnings (NASDAQ:EXEL)” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/02/01/fy2017-earnings-estimate-for-exelixis-inc-issued-by-leerink-swann-exel.html.
Exelixis, Inc is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company’s cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors.
Get a free copy of the Zacks research report on Exelixis (EXEL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.